-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IVcQBKHYs2gZ39xC31zKcTcDel0GD/StGdz+wdLeJTTZ8tCGfxbXGMMExO0/gGBe A6SyRXrtg5PlyTb1wH2P/g== 0001047469-99-011326.txt : 19990326 0001047469-99-011326.hdr.sgml : 19990326 ACCESSION NUMBER: 0001047469-99-011326 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19990325 GROUP MEMBERS: BIOTECHNOLOGY VALUE FUND L P GROUP MEMBERS: BVF INC. GROUP MEMBERS: BVF PARTNERS L.P. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: GENOME THERAPEUTICS CORP CENTRAL INDEX KEY: 0000356830 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 042297484 STATE OF INCORPORATION: MA FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-34935 FILM NUMBER: 99572660 BUSINESS ADDRESS: STREET 1: 1OO BEAVER ST CITY: WALTHAM STATE: MA ZIP: 02154 BUSINESS PHONE: 6178935007 MAIL ADDRESS: STREET 1: 100 BEAVER STREET CITY: WALTHAM STATE: MA ZIP: 02154 FORMER COMPANY: FORMER CONFORMED NAME: COLLABORATIVE RESEARCH INC DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND L P CENTRAL INDEX KEY: 0000918923 STANDARD INDUSTRIAL CLASSIFICATION: INVESTMENT ADVICE [6282] IRS NUMBER: 363924731 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 227 W MONROE STREET, SUITE 4800 STREET 2: 227 W MONROE STREET, SUITE 4800 CITY: CHICAGO STATE: IL ZIP: 60606 MAIL ADDRESS: STREET 1: 227 W MONROE STREET, SUITE 4800 STREET 2: 227 W MONROE STREET, SUITE 4800 CITY: CHICAGO STATE: IL ZIP: 60606 SC 13D/A 1 SCHEDULE 13-D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 3)(1) GENOME THERAPEUTICS CORPORATION ------------------------------- (Name of Issuer) Common Stock ------------ (Title of Class of Securities) 372430 10 8 ----------- (CUSIP Number) Hope Flack BVF Partners L.P. 227 West Monroe Drive, Suite 4800 Chicago, Illinois 60606 (312) 263-7777 -------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 23, 1998 ----------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box / /. Check the following box if a fee is being paid with the statement / /. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.) NOTE: Six copies of this statement, including all exhibits, should be filed with the Commission. SEE Rule 13d-1(a) for other parties to whom copies are to be sent. (Continued on following pages) (Page 1 of 7 Pages) - ------------------ (1) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). - --------------------- ----------------- CUSIP NO. 372430 10 8 13D Page 2 of 7 Pages - --------------------- ----------------- - ------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS BIOTECHNOLOGY VALUE FUND, L.P. - ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /X/ (b) / / - ------------------------------------------------------------------------------- 3 SEC USE ONLY - ------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC - ------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) / / - ------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE - ------------------------------------------------------------------------------- NUMBER 7 SOLE VOTING POWER OF -0- SHARES -------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER OWNED BY 824,763 REPORTING -------------------------------------------- PERSON 9 SOLE DISPOSITIVE POWER WITH -0- -------------------------------------------- 10 SHARED DISPOSITIVE POWER 824,763 - ------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 824,763 - ------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES* / / - ------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 4.5% - ------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* PN - ------------------------------------------------------------------------------- * SEE INSTRUCTIONS BEFORE FILLING OUT! - --------------------- ----------------- CUSIP NO. 372430 10 8 13D Page 3 of 7 Pages - --------------------- ----------------- - ------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS BVF PARTNERS L.P. - ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /X/ (b) / / - ------------------------------------------------------------------------------- 3 SEC USE ONLY - ------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC - ------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) / / - ------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE - ------------------------------------------------------------------------------- NUMBER 7 SOLE VOTING POWER OF -0- SHARES -------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER OWNED BY 1,552,089 REPORTING -------------------------------------------- PERSON 9 SOLE DISPOSITIVE POWER WITH -0- -------------------------------------------- 10 SHARED DISPOSITIVE POWER 1,552,089 - ------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,552,089 - ------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES* / / - ------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 8.5% - ------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* PN - ------------------------------------------------------------------------------- * SEE INSTRUCTIONS BEFORE FILLING OUT! - --------------------- ----------------- CUSIP NO. 372430 10 8 13D Page 4 of 7 Pages - --------------------- ----------------- - ------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS BVF INC. - ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /X/ (b) / / - ------------------------------------------------------------------------------- 3 SEC USE ONLY - ------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC - ------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) / / - ------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE - ------------------------------------------------------------------------------- NUMBER 7 SOLE VOTING POWER OF -0- SHARES -------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER OWNED BY 1,769,285 REPORTING -------------------------------------------- PERSON 9 SOLE DISPOSITIVE POWER WITH -0- -------------------------------------------- 10 SHARED DISPOSITIVE POWER 1,769,285 - ------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,769,285 - ------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES* / / - ------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 9.6% - ------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* IA, CO - ------------------------------------------------------------------------------- * SEE INSTRUCTIONS BEFORE FILLING OUT! - --------------------- ----------------- CUSIP NO. 372430 10 8 13D Page 5 of 7 Pages - --------------------- ----------------- This Amendment No. 3 (this "Amendment") relates to the Statement on Schedule 13D, dated March 20, 1995, and filed with the Securities and Exchange Commission (the "SEC") on March 28, 1995, as amended by Amendment No. 1, dated July 21, 1995 and Amendment No.2, dated February 22, 1996 filed with the SEC on behalf of Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF"), BVF Partners L.P., a Delaware limited partnership ("BVF Partners"), and BVF Inc., a Delaware corporation ("BVF Inc."), with respect to the common stock, par value $0.10 (the "Stock"), of Genome Therapeutics Corporation ("Genome"). ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. Since January 20, 1999, Partners, in its capacity as general partner of BVF, has purchased on behalf of such limited partnership an aggregate number of 369,400 shares of the Stock for an aggregate consideration of $1,159,790.94, utilizing funds provided by BVF from its working capital pursuant to the terms of its limited partnership agreement with Partners. In addition, Partners, in its capacity as investment manager with respect to certain other accounts, has purchased on behalf of such accounts an aggregate number of 349,300 shares of the Stock for an aggregate consideration of $1,101,610.55, utilizing funds under management by Partners pursuant to investment management agreements between Partners and such accounts. The managed accounts on whose behalf BVF Partners owns shares of the Stock are Investment 10 L.L.C., an Illinois limited liability company ("ILL10"), Palamundo, L.D.C., a limited duration company organized under the laws of the Cayman Islands ("Palamundo"), ZPG Securities, L.L.C., a New York limited liability company ("ZPG"), and Biotechnology Value Fund, Ltd., a Cayman Islands Corporation ("BVF Ltd."). The managed accounts on whose behalf BVF Inc. owns shares of the Stock are Biotech 1 Investment L.L.C., an Illinois limited liability company ("Biotech 1"), and Biotech 2 Investment L.L.C., an Illinois limited liability company ("Biotech 2"). ILL10, ZPG, Palamundo, BVF Ltd., Biotech 1 and Biotech 2 are collectively referred to herein as the "Accounts." The Accounts specialize in holding biotechnology stocks for investment purposes and the business address of each is Grosvenor Capital Management, L.P., 227 West Monroe Drive, Suite 4800, Chicago, Illinois 60606. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. (a) BVF beneficially owns 824,763 shares of the Stock, BVF Partners beneficially owns 1,552,089 shares of the Stock and BVF Inc. beneficially owns 1,769,285 shares of the Stock, approximately 4.5%, 8.5% and 9.6%, respectively, of the aggregate number of shares outstanding as of January 11, 1999 (as reported in Genome's most recent quarterly statement on Form 10-Q). (b) BVF shares voting and dispositive power over the 824,763 shares of the Stock it beneficially owns with BVF Partners. BVF Partners shares voting and dispositive power over the 1,552,089 shares of the Stock it beneficially owns with, in addition to BVF, BVF Inc. and the managed account on whose behalf BVF Partners, as investment manager, purchased such shares. BVF Inc. shares voting and dispositive power over the 1,769,285 shares of the Stock it beneficially owns with BVF, BVF Partners and the managed accounts on whose behalf BVF Inc., as investment manager, purchased such shares. - --------------------- ----------------- CUSIP NO. 372430 10 8 13D Page 6 of 7 Pages - --------------------- ----------------- (c) Exhibit B attached hereto contains information as to all transactions in the Stock by the Reporting Persons during the last 60 days. All such transactions were made for cash in open market, over-the-counter transactions. Except as provided below, no other transactions in the Stock have been effected by the Reporting Persons during the last 60 days. On January 26, 1999, Partners transferred 11,275 shares of Stock that it owned on behalf of Palamundo to BVF and transferred 9,225 shares of Stock that it owned on behalf of Palamundo to BVF, Ltd. Additionally, on February 11, 1999, Partners transferred 8,000 shares of Stock that it owned on behalf of ILL10 to BVF and transferred 6,000 shares of Stock that it owned on behalf of ILL10 to BVF, Ltd. The aggregate number of shares of the Stock beneficially owned by Partners and BVF Inc. was not affected by these transfers. (d) The Accounts are entitled to receive dividends and any sale proceeds with respect to the Stock in proportion to their respective ownership interests therein. Item 7 is hereby amended to read in its entirety as follows: ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. Exhibit A - Agreement Regarding Joint Filing Exhibit B - Transactions in the Stock by the Reporting Persons during the last 60 days. - --------------------- ----------------- CUSIP NO. 372430 10 8 13D Page 7 of 7 Pages - --------------------- ----------------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: March 24, 1999 BIOTECHNOLOGY VALUE FUND, L.P. By: BVF Partners L.P., its general partner By: BVF Inc., its general partner By: /s/ MARK N. LAMPERT --------------------------------- Mark N. Lampert President BVF PARTNERS L.P. By: BVF Inc., its general partner By: /s/ MARK N. LAMPERT --------------------------------- Mark N. Lampert President BVF INC. By: /s/ MARK N. LAMPERT --------------------------------- Mark N. Lampert President EXHIBIT A AGREEMENT REGARDING JOINT FILING The undersigned, Biotechnology Value Fund, L.P., a Delaware limited partnership, and BVF Partners L.P., a Delaware limited partnership, and BVF Inc., a Delaware corporation, hereby agree and acknowledge that the Amendment containing the information required by Schedule 13D, to which this Agreement is attached as an exhibit, is filed on behalf of each of them. The undersigned further agree that any further amendments or supplements thereto shall also be filed on behalf of each of them. Dated: March 24, 1999 BIOTECHNOLOGY VALUE FUND, L.P. By: BVF Partners L.P., its general partner By: BVF Inc., its general partner By: /s/ MARK N. LAMPERT --------------------------------- Mark N. Lampert President BVF PARTNERS L.P. By: BVF Inc., its general partner By: /s/ MARK N. LAMPERT --------------------------------- Mark N. Lampert President BVF INC. By: /s/ MARK N. LAMPERT --------------------------------- Mark N. Lampert President EXHIBIT B TRANSACTIONS IN THE STOCK BY THE REPORTING PERSONS DURING THE PAST SIXTY DAYS
- -------------------------------------------------------------------------------------------------- Trade Date By For the Account of Quantity Price per Share Type of Trade Broker ---------- -- ------------------ -------- --------------- ------------- ------ 02/25/99 Partners ILL10 2,000 $3.2500 Purchase INET - -------------------------------------------------------------------------------------------------- 02/26/99 Partners BVF 6,000 $3.2500 Purchase INET - -------------------------------------------------------------------------------------------------- 02/26/99 Partners ILL10 3,500 $3.2500 Purchase INET - -------------------------------------------------------------------------------------------------- 02/26/99 Partners BVF Ltd. 10,000 $3.2500 Purchase INET - -------------------------------------------------------------------------------------------------- 03/01/99 Partners BVF 6,000 $3.3059 Purchase INET - -------------------------------------------------------------------------------------------------- 03/01/99 Partners ILL10 2,900 $3.3059 Purchase INET - -------------------------------------------------------------------------------------------------- 03/01/99 Partners ZPG 2,000 $3.3059 Purchase INET - -------------------------------------------------------------------------------------------------- 03/01/99 Partners BVF Ltd. 22,000 $3.3059 Purchase INET - -------------------------------------------------------------------------------------------------- 03/02/99 Partners BVF 3,000 $3.3125 Purchase INET - -------------------------------------------------------------------------------------------------- 03/02/99 Partners BVF Ltd. 2,000 $3.3125 Purchase INET - -------------------------------------------------------------------------------------------------- 03/03/99 Partners BVF 6,000 $3.2500 Purchase INET - -------------------------------------------------------------------------------------------------- 03/03/99 Partners ILL10 1,500 $3.2500 Purchase INET - -------------------------------------------------------------------------------------------------- 03/04/99 Partners BVF 4,000 $3.1875 Purchase INET - -------------------------------------------------------------------------------------------------- 03/04/99 Partners BVF Ltd. 4,000 $3.1875 Purchase INET - -------------------------------------------------------------------------------------------------- 03/05/99 Partners BVF 4,600 $3.1250 Purchase INET - -------------------------------------------------------------------------------------------------- 03/15/99 Partners BVF 2,000 $3.0625 Purchase INET - -------------------------------------------------------------------------------------------------- 03/16/99 Partners BVF 225,000 $3.1250 Purchase JONE - -------------------------------------------------------------------------------------------------- 03/16/99 Partners ILL10 5,000 $3.1250 Purchase JONE - -------------------------------------------------------------------------------------------------- 03/16/99 Partners BVF Ltd. 190,000 $3.1250 Purchase JONE - -------------------------------------------------------------------------------------------------- 03/16/99 Partners BVF 31,800 $3.1048 Purchase INET - --------------------------------------------------------------------------------------------------
- -------------------------------------------------------------------------------------------------- Trade Date By For the Account of Quantity Price per Share Type of Trade Broker ---------- -- ------------------ -------- --------------- ------------- ------ - -------------------------------------------------------------------------------------------------- 03/16/99 Partners BVF Ltd. 25,000 $3.1048 Purchase INET - -------------------------------------------------------------------------------------------------- 03/17/99 Partners BVF 27,000 $3.1250 Purchase INET - -------------------------------------------------------------------------------------------------- 03/17/99 Partners BVF Ltd. 23,000 $3.1250 Purchase INET - -------------------------------------------------------------------------------------------------- 03/19/99 Partners BVF 9,000 $3.1136 Purchase INET - -------------------------------------------------------------------------------------------------- 03/19/99 Partners ILL10 5,400 $3.1136 Purchase INET - -------------------------------------------------------------------------------------------------- 03/19/99 Partners BVF Ltd. 9,000 $3.1136 Purchase INET - -------------------------------------------------------------------------------------------------- 03/22/99 Partners BVF 45,000 $3.1250 Purchase INET - -------------------------------------------------------------------------------------------------- 03/22/99 Partners ILL10 5,000 $3.1250 Purchase INET - -------------------------------------------------------------------------------------------------- 03/22/99 Partners BVF Ltd. 37,000 $3.1250 Purchase INET - --------------------------------------------------------------------------------------------------
INET = Instinet JONE = Jones & Associates -----END PRIVACY-ENHANCED MESSAGE-----